Drug Profile
AP 1100
Alternative Names: AP-1100Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Ariel Pharmaceuticals
- Class Cytoprotectives; Neuroprotectants
- Mechanism of Action Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haemorrhagic shock
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Haemorrhagic shock in USA (IV)
- 23 Sep 2011 Phase-I development is ongoing in USA